CompletedPhase 1/2

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

United States29 participantsStarted 2021-09-03

Plain-language summary

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants must be able to provide an archived tumor sample * Histologically or cytologically confirmed solid tumors with KRAS G12C mutation * Must have received at least 1 prior standard therapy * Must have at least 1 measurable lesion per RECIST v1.1 * Must have adequate organ function * Must be able to swallow and retain orally administered medication Exclusion Criteria: * Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days * Active infection requiring systemic treatment within 7 days * Active HBV or HCV * Any severe and/or uncontrolled medical conditions * LVEF ≤50% assessed by ECHO or QTcF * QT interval \>470 msec * Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)

Timeframe: At the end of Cycle 1 (each cycle is 21 days)

Dose Escalation and Dose Expansion phase: Number of participants with adverse events

Timeframe: Up to 4 years

Dose Expansion phase: Overall response rate (ORR)

Timeframe: Up to 4 years - from baseline to RECIST confirmed Progressive Disease

Dose Expansion phase: Duration of response ( DOR )

Timeframe: Up to 4 years

Trial details

NCT IDNCT05002270

SponsorJacobio Pharmaceuticals Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02-12

View on ClinicalTrials.gov More Advanced Solid Tumor trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)

Timeframe: At the end of Cycle 1 (each cycle is 21 days)

Dose Escalation and Dose Expansion phase: Number of participants with adverse events

Timeframe: Up to 4 years

Dose Expansion phase: Overall response rate (ORR)

Timeframe: Up to 4 years - from baseline to RECIST confirmed Progressive Disease

Dose Expansion phase: Duration of response ( DOR )

Timeframe: Up to 4 years